Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safimaltib and Ibrutinib in Relapsed/Refractory B-Cell NHL and CLL
NCT04876092Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of JNJ-67856633 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicity at 21 days and Percentage of Participants with Adverse Events. Started Jul 2021; status: completed.
02
Drugs
JNJ-67856633
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04876092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876092.